Plasma triglyceride levels increase the risk for recurrent vascular events independent of LDL-cholesterol or nonHDL-cholesterol

被引:40
|
作者
van de Woestijne, Anton P. [1 ]
Wassink, Annemarie M. J. [1 ]
Monajemi, Houshang [1 ]
Liem, An-Ho [2 ]
Nathoe, Hendrik M. [3 ]
van der Graaf, Yolanda [4 ]
Visseren, Frank L. J. [1 ]
机构
[1] Univ Med Ctr Utrecht, Dept Vasc Med, NL-3508 GA Utrecht, Netherlands
[2] Admiraal De Ruyter Ziekenhuis, Dept Cardiol, Goes, Netherlands
[3] Univ Med Ctr Utrecht, Dept Cardiol, NL-3508 GA Utrecht, Netherlands
[4] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, NL-3508 GA Utrecht, Netherlands
关键词
Triglycerides; Lipoproteins; Vascular disease; Secondary prevention; DENSITY-LIPOPROTEIN CHOLESTEROL; CORONARY-HEART-DISEASE; APOLIPOPROTEIN-B; THERAPY; MECHANISMS;
D O I
10.1016/j.ijcard.2012.01.008
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Plasma triglyceride (TG) levels are known to confer an increased risk of vascular disease in healthy populations, but data in high-risk patients are scarce. In this study we evaluated the risk on recurrent vascular events conferred by increased plasma TG levels in patients with various clinical manifestations of vascular disease. Methods: Prospective cohort study of 5731 patients with clinically manifest vascular disease. Results: First new vascular events (myocardial infarction, ischemic stroke, vascular death) occurred in 782 subjects during a median follow-up of 4.9 years (interquartile range 2.5-8.1 years). Patients in the highest plasma TG quintile (>2.24 mmol/L) had a higher risk for recurrent vascular events (HR 1.45; 95%CI 1.13-1.86) compared with the lowest plasma TG quintile (<0.97 mmol/L) after adjustments for age, gender, body mass index, smoking, lipid-lowering medication and low-density lipoprotein-cholesterol. The increased risk associated with increasing plasma TG levels was irrespective of the presence of type 2 diabetes (T2DM), but only present in patients without the metabolic syndrome. Furthermore, the increased risk was particularly present in patients with coronary artery disease (CAD) (HR 1.45; 95% CI 1.02-2.08) and was not modified by other lipid levels (p-value for interaction >0.05). Plasma TG still contributed to vascular risk when other lipid levels were at target level. Conclusions: Higher plasma TG levels are associated with increased risk for recurrent vascular events, in particular in CAD patients. This increased risk is independent of the presence of T2DM and the use of lipid-lowering medication and is not modified by other lipid levels. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:403 / 408
页数:6
相关论文
共 50 条
  • [31] Discordance between lipoprotein (a) and LDL-cholesterol levels in cardiovascular risk assessment in apparently healthy subjects
    Bergmann, Katarzyna
    Stefanska, Anna
    Krintus, Magdalena
    Sypniewska, Grazyna
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2023, 33 (07) : 1429 - 1436
  • [32] Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the cholesterol and recurrent events trial
    Sacks, FM
    Moyé, LA
    Davis, BR
    Cole, TG
    Rouleau, JL
    Nash, DT
    Pfeffer, MA
    Braunwald, E
    CIRCULATION, 1998, 97 (15) : 1446 - 1452
  • [33] PLASMA-LEVELS OF VLDL-CHOLESTEROL + LDL-CHOLESTEROL, HDL-CHOLESTEROL, TRIGLYCERIDES AND APOPROTEINS-B AND A-I IN A HEALTHY POPULATION - INFLUENCE OF SEVERAL RISK-FACTORS
    DEDONDERDECOOPMAN, E
    FIEVETDESREUMAUX, C
    CAMPOS, E
    MOULIN, S
    DEWAILLY, P
    SEZILLE, G
    JAILLARD, J
    ATHEROSCLEROSIS, 1980, 37 (04) : 559 - 568
  • [34] The cardiovascular risk reduction benefits of a low-carbohydrate diet outweigh the potential increase in LDL-cholesterol
    Wood, Thomas R.
    Hansen, Robert
    Sigurdsson, Axel F.
    Johannsson, Gudmundur F.
    BRITISH JOURNAL OF NUTRITION, 2016, 115 (06) : 1126 - 1128
  • [35] Plasma lipoprotein(a) levels and LDL-cholesterol lowering response to statin therapy in patients with heterozygous familial hypercholesterolemia
    Miltiadous, George
    Saougos, Vasilios
    Cariolou, Marios
    Elisaf, Moses S.
    ANNALS OF CLINICAL AND LABORATORY SCIENCE, 2006, 36 (03): : 353 - 355
  • [36] A Western-Fed Diet Increases Plasma HDL and LDL-Cholesterol Levels in ApoD-/- Mice
    Ali, Kamilah
    Abo-Ali, Ehab M.
    Kabir, M. D.
    Riggins, Bethany
    Nguy, Susanna
    Li, Lisa
    Srivastava, Ujala
    Thinn, Su Mya Mya
    PLOS ONE, 2014, 9 (12):
  • [37] Increased plasma LDL-cholesterol levels following cholecystokinin-5 induced panic attacks in males
    Bailey, DL
    Castillo-Abadia, M
    Lara, N
    Gil, L
    Jhangri, G
    Archer, S
    Baker, G
    Le Mellédo, J
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 : S369 - S370
  • [38] Plasma lipoprotein (a) levels and LDL-cholesterol lowering response to statin therapy in patients with heterozygous familial hypercholesterolaemia
    Miltiadous, G.
    Cariolou, M.
    Mitrogianni, Z. O. I.
    Doumas, M.
    Saougkos, V.
    Bairaktari, E.
    Elisaf, M.
    ATHEROSCLEROSIS SUPPLEMENTS, 2006, 7 (03) : 530 - 530
  • [39] LDL-cholesterol target levels achievement in high-risk patients: An (un)expected gender bias
    Berteotti, Martina
    Nreu, Besmir
    Casolo, Giancarlo
    Zuppiroli, Alfredo
    Mannucci, Edoardo
    Marcucci, Rossella
    Francesconi, Paolo
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2024, 34 (01) : 145 - 152
  • [40] ACTIVATION OF THE NUCLEAR RECEPTOR PXR DECREASES PLASMA LDL-CHOLESTEROL LEVELS AND INDUCES HEPATIC STEATOSIS IN LDL RECEPTOR KNOCKOUT MICE
    Hoekstra, M.
    Lammers, B.
    Out, R.
    Li, Z.
    van Eck, M.
    van Berkel, T.
    ATHEROSCLEROSIS SUPPLEMENTS, 2009, 10 (02)